德国来源ONC201治疗H3K27变异儿童脑桥弥漫性中线胶质瘤的初步发现
这项回顾性分析纳入2016年1月至2022年7月治疗的27例H3K27变异儿童脑桥弥漫性中线胶质瘤患者,其中18例接受德国来源ONC201治疗。ONC201组中位总生存期19.9个月,非ONC201组10.9个月;ONC201组仅2例出现疲劳副作用。作者认为ONC201可能改善总生存期且无显著副作用,但因回顾性设计及偏倚需谨慎解读,需进一步随机临床研究验证。
要点
- 27例H3K27变异儿童脑桥弥漫性中线胶质瘤患者中,18例接受德国来源ONC201治疗。
- ONC201组中位总生存期19.9个月,非ONC201组10.9个月。
- ONC201组仅2例出现疲劳副作用,4例进展后接受再放疗。
核心结论
- 本研究提示德国来源ONC201可能改善H3K27变异儿童脑桥弥漫性中线胶质瘤患者的总生存期且无显著副作用,但因回顾性设计及偏倚需谨慎解读,需进一步随机临床研究验证。
研究设计与样本
- 回顾性分析纳入2016年1月至2022年7月治疗的H3K27变异儿童脑桥弥漫性中线胶质瘤患者,所有患者经立体定向活检获取组织行免疫组化和分子分型。
- 所有患者接受放疗同步替莫唑胺,能获得德国来源ONC201者接受其单药治疗直至进展,无法获得者接受其他化疗方案。
主要发现
- 27例患者中位年龄5.6岁(范围3.4-17.9),其中18例接受德国来源ONC201治疗。
- 随访期间16例(59.3%)出现进展,德国来源ONC201组进展发生率倾向于更低但无统计学显著性。
- 德国来源ONC201组中位总生存期19.9个月,非德国来源ONC201组10.9个月。
- 德国来源ONC201组仅2例出现疲劳副作用,该组18例中4例进展后接受再放疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需谨慎解读,因研究为回顾性设计且存在偏倚。
- 原文指出需进一步随机临床研究验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: H3K27 altered pediatric pontine diffuse midline gliomas (pDMG) have a poor prognosis, and conventional treatments offer limited benefits. However, recent advancements in molecular evaluations and targeted therapies have shown promise. The aim of this retrospective analysis was to evaluate the effectiveness of German-sourced ONC201, a selective antagonist of dopamine receptor DRD2, for the treatment of pediatric H3K27 altered pDMGs. METHODS: Pediatric patients with H3K27 altered pDMG treated between January 2016 and July 2022 were included in this retrospective analysis. Tissue samples were acquired from all patients via stereotactic biopsy for immunohistochemistry and molecular profiling. All patients received radiation treatment with concurrent temozolomide, and those who could acquire GsONC201 received it as a single agent until progression. Patients who could not obtain GsONC201 received other chemotherapy protocols. RESULTS: Among 27 patients with a median age of 5.6 years old (range 3.4-17.9), 18 received GsONC201. During the follow-up period, 16 patients (59.3%) had progression, although not statistically significant, the incidence of progression tended to be lower in the GsONC201 group. The median overall survival (OS) of the GsONC201 group was considerably longer than of the non-GsONC201 group (19.9 vs. 10.9 months). Only two patients receiving GsONC201 experienced fatigue as a side effect. 4 out of 18 patients in the GsONC201 group underwent reirradiation after progression. CONCLUSION: In conclusion, this study suggests that GsONC201 may improve OS in pediatric H3K27-altered pDMG patients without significant side effects. However, caution is warranted due to retrospective design and biases, highlighting the need for further randomized clinical studies to validate these findings.
引用
- Tanrıkulu B, Yaşar AH, Canpolat C, et al. Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas. J Neurooncol. 2023. PMID: 37402093. doi:10.1007/s11060-023-04347-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。